The steady, inevitable decline of amyotrophic lateral sclerosis patients

Consultant Pharmacist

Volumn 20, Issue 10, 2005, Pages 803-812

  Zanni, Guido R ^a   Wick, Jeannette Y ^b  

^a National Institutes of Health ^*

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Fasciculations; Lou Gehrig's disease; Motor neurons; Riluzole

Indexed keywords

AMANTADINE; AMITRIPTYLINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATROPINE; BENZATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOPHOSPHAMIDE; DEXTROMETHORPHAN; GABAPENTIN; GLIAL DERIVED GROWTH FACTOR; GLUTAMIC ACID; GLYCOPYRRONIUM BROMIDE; GROWTH FACTOR; LAMOTRIGINE; LEVAMISOLE; MINOCYCLINE; MORPHINE; OPIATE DERIVATIVE; RILUZOLE; SCOPOLAMINE; SELEGILINE; SOMATOMEDIN; TRIHEXYPHENIDYL;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DYSPNEA; ELECTROMYOGRAPHY; ENVIRONMENTAL EXPOSURE; FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS; FASCICULATION; FATIGUE; GENE; GENE MUTATION; HUMAN; HYPERSALIVATION; INCIDENCE; MOTONEURON; MOUTH DISCOMFORT; MUSCLE BIOPSY; MUSCLE WEAKNESS; NAUSEA; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; ORAL PARESTHESIA; ORAL TINGLING; OXIDATIVE STRESS; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PNEUMONIA; PRACTICE GUIDELINE; RESPIRATORY CARE; REVIEW; RISK FACTOR; SEROLOGY; SIDE EFFECT; SOD1 GENE; SPASTICITY; SPORADIC AMYOTROPHIC LATERAL SCLEROSIS; SYMPTOMATOLOGY; TOBACCO; VOMITING; WEAKNESS;

EID: 33845259346     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2005.803     Document Type: Review

References (32)

1. National Institute of Neurological Disorders and Stroke. Amyotrophic lateral sclerosis fact sheet. Available at http://www.ninds.nih.gov.
2. Lai EC. Therapeutic developments in amyotrophic lateral sclerosis. Expert Opin Investig Drugs 1999;8:347-61.
3. Lomen-Hoerth C, Murphy J, Langmore S et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094-7.
4. Wicklund MP. Amyotrophic lateral sclerosis: possible role of environmental influences. Neurol Clin 2005;23:461-84.
5. National Institute of Neurological Disorders and Stroke. NINDS amyotrophic lateral sclerosis information page. Available at http://www.ninds.nih.gov.
6. Miller RG, Rosenberg JA, Gelinas DF et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311-23.
7. Cudkowicz M, Qureshi M, Shefner J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 2004;1:273-83.
8. Friedrich MJ. Experimental therapies hold promise for treating amyotrophic lateral sclerosis. JAMA 2005;293:1048-9.
9. Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992;55:1106-15.
10. Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis: I. Preliminary report on geographic distribution and special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954;4:438-48.
11. Sejvar JJ, Holman RC, Bresee JS et al. Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 2005;25:144-52.
12. Ajdacic-Gross V, Wang J, Gutzwiller F. Season of birth in amyotrophic lateral sclerosis. Eur J Epidemiol 1998;14:359-61.
13. Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996;47(6, suppl 4):s22f-s227.
14. Trotti D, Danbolt NC, Volterra A. Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 1998;19:328-34.
15. Liu D, Yang R, Yan X, McAdoo DJ. Hydroxyl radicals generated in vivo kill neurons in the rat spinal cord: electrophysiological, histological, and neurochemical results. J Neurochem 1994;62:37-44.
16. Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-57.
17. Vinceti M, Guidetti D, Bergomi M et al. Lead, cadmium, and selenium in the blood of patients with sporadic amyotrophic lateral sclerosis. Ital J Neurol Sci 1997;18:87-92.
18. Kamel F, Umbach DM, Munsat TL et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 1999;18:194-202.
19. Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington state. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000;151:156-63.
20. Weisskopf MG, McCullough ML, Calle EE et al. A prospective study of cigarette smoking and amyotrophic lateral sclerosis. Am J Epidemiol 2004;160:26-33.
21. Belli S, Vanacore N. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? Eur J Epidemiol 2005;20:237-42.
22. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91.
23. Bradley WG, Anderson F, Gowda N et al. ALS CARE Study Group. Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:240-4.
24. Pharmaceutical Manufacturer Package Insert. Rilutek [package insert]. Bridgewater, NJ: Aventis Pharmaceutical Inc.; September 2004.
25. Servera E, Sancho J. Appropriate management of respiratory problems is of utmost importance in the treatment of patients with amyotrophic lateral sclerosis. Chest 2005;127:1879-82.
26. Ensrud E. Patient page. Can computers read your mind? Neurology 2005;64:E30-E31.
27. Kubler A, Nijboer F, Mellinger J et al. Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface. Neurology 2005;64:1775-7.
28. Fernandez-Gomez FJ, Galindo MF, Gomez-Lazaro M et al. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 2005;133:959-67.
29. Kieran D, Kalmar B, Dick JR et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5.
30. Benn SC, Brown RH Jr. Putting the heat on ALS. Nat Med 2004;10:345-7.
31. Phase II trial for ALS expected to begin after second quarter. Vaccine Weekly July 20, 2005.
32. Clement AM, Nguyen MD, Roberts EA et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003;302:113-7.